Marshall Wace
LCTX icon

Marshall Wace’s Lineage Cell Therapeutics LCTX Stock Holding History

Marshall Wace’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.84M Buy
3,065,033
+1,702,972
+125% +$2.87M 0.01% 1323
2025
Q4 		$2.27M Buy
+1,362,061
New +$2.36M ﹤0.01% 1517
2023
Q2 		– Sell
-55,646
Closed -$83.5K – 2769
2023
Q1 		$83.5K Buy
55,646
+18,528
+50% +$25.9K ﹤0.01% 2511
2022
Q4 		$43.4K Sell
37,118
-6,709
-15% -$8.46K ﹤0.01% 2843
2022
Q3 		$50K Buy
+43,827
New +$64.4K ﹤0.01% 3241
2021
Q3 		– Sell
-186,940
Closed -$533K – 3283
2021
Q2 		$533K Buy
+186,940
New +$484K ﹤0.01% 2098

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return